Life Sciences Archive » November, 2012

Life Sciences - November, 2012

237 articles

• Ranbaxy Halts Production Of Generic Lipitor
• Sunshine Rule For Physician Payments Moves Forward
• Ex-Penn State Prof. Gets 41 Months For $3M Grant Fraud
• Life Sciences MVP: Covington's John Hurvitz
• Supreme Court Takes Up Appeal Of Post-Mensing Ruling
• High Court Takes Up Myriad Gene Patent Case
• Law360 MVP Awards Go To Legal Top Guns From 52 Firms
• Firm Broke Agreement Over GSK Denture Deal: Kline & Specter
• Takeda Hits Lupin With IP Suit Over Acid Reflux Drug
• 8th Circ. Reverses $1.1M Levaquin Punitive Damages Award
• US Tells High Court Not To Hear Claim Construction Case
• Ex-Takeda Contractor Says New Evidence Revives $6B FCA Suit
• Shire Unit Can't Escape Genzyme False Advertising Suit
• Cosmetics Under Fire: Tips To Avoid FDA Scrutiny
• Highlights Of The New EU Framework For Medical Devices
• Calif. High Court Snubs Price-Fixing Case Against Pfizer, Others
• AstraZeneca Opposes MDL In Nexium Bone Density Suits
• FDA Urged To Give Troubled Compounders A 2nd Look
• 2nd Circ. Backs Another Lilly Win In Zyprexa Warning MDL
• GSK Hit With Suit Over Avodart's Prostate Cancer Risks
• Ex-Baseball Player Indicted For Insider Trading On Abbot Buy
• 8th Circ. Shields Holding Co. From ACA Contraceptive Rule
• St. Jude's Rival Says Co. Flouted Heart Monitor Patent
• Investors Get Class Cert. Over Radient Pharma False Claims
• Bayer Targets Lupin Over Generic Natazia
• How Healthy Is Your Law Firm? Time For A Stress Test
• Nexium Maker Wants Antitrust Claims Handled By Patent Judge
• Lender Wants AstraZeneca Affiliate's Ch. 11 Case Tossed
• Labeling Changes, Not Ban, On Horizon For Energy Drinks
• UK Courts Can Hear Foreign Patent Cases, Judge Rules
• Sidley Austin Nabs Seasoned Ex-FDA Counsel
• NECC Fails To Win Stay In Mass. Meningitis Suits
• Fed. Circ. Won't Rethink Alimta Double Patenting Decision
• Perrigo Settles With Cadence Over Ofirmev Generic Plans
• Mensing Bars Generic Reglan Suits, Drug Cos. Tell Pa. Court
• Stryker, Howmedica To Face Renewed Implant Defect Suit
• Smith & Nephew Pays $782M For Texas Wound Care Co.
• SEC Reportedly Weighing Insider Trading Suit Against SAC
• New ACA Rules Foggy On Drug Coverage, Multistate Plans
• Atty Released From 3M's Defamation Suit After Reaching Deal
• DaVita Hit With FCA Suit Over Alleged Medicare Violations
• FDA Floats State Enforcement Of New Compounder Standards
• Tweaking Brand-Name Drugs Can Hurt Competition, FTC Says
• Texas AG Blasts Subpoena In $421M FCA Suit
• Medtronic Says Off-Label Marketing FCA Claims Fall Short
• BioMimetic Investor Says $380M Buyout Deal Doesn't Cut It
• FDA Says Guidelines On Device Review, Recalls Are Priorities
• Ex-SAC Manager Accused Of Insider Trading Freed On $5M Bail
• DC Circ. Blocks CVS Challenge To DEA License Suspensions
• Mass. Health Panel OKs Free Meals From Drug, Device Makers
• NBTY Nibbles At Health Snack Market With $78M Balance Buy
• GlycoBioSciences Says Skin Ointment Infringed 2 Patents
• Early Steps Toward Developing US Nanopesticide Policy
• Heller Ehrman Skirts $100M Malpractice Claim Over IP Mishap
• Court Limits Contract Claims In Medicare Billing Disputes
• Vitamin C Co. Needn't Yield Audit Docs In Price-Fixing MDL
• Judge Won't Subject All Fosamax MDL Claims To Lone Pine
• FDA Report Faults St. Jude For Handling Of Heart Device
• Pfizer Calls Out Kaiser Over Contradictory Neurontin Claims
• NJ Mulls New Compounding Pharmacy Law Following Outbreak
• FDA's Push For Compounding Oversight Meets Skepticism
• Investors Say Pfizer Destroyed Files On Celebrex, Bextra
• Ignorance Could Be Bliss For SAC's Cohen In Tipping Case
• Eisai Says Zurich Policy Covers Off-Label FCA Suit
• 2nd Circ. Backs Lilly Win In Drug Label Warning MDL
• Millennium Sues Generic-Drug Maker Over Velcade Plans
• Diabetes Test Strip Suppliers Should Expect Audits
• Ob-Gyns Back Over-The-Counter Birth Control Sales
• Norwegian Fish Oil Firm Accepts $847M Offer From BASF
• Illumina Presses $113.3M Bid For DNA Sequencer
• New Drugs, Deals Put Pharma Under Insider Trading Microscope
• Bayer Bows Out Of Bidding War For Schiff Nutrition
• White House Releases ACA Rules On Exchanges, Wellness Plans
• Apotex Targets Exclusivity Period In Generic Benicar Suit
• NECC Ducks Asset Restriction Bid In Meningitis Case For Now
• Pain Therapeutics Can't Duck Investors' Remoxy Suit
• Fed. Circ. Nixes Intema Fetal Test Patent Under Mayo
• High Court To Mull Attys' Fees For Time-Barred Vaccine Claims
• Momenta To Take Generic Lovenox Fight To Supreme Court
• Merck Says High Court Should Hear 2 Pay-For-Delay Cases
• J&J Wants Out Of Ex-Sales Reps' Suit Over Noncompete Deal
• SAC Manager Arrested In $276M Insider Trading Case
• Antitrust Issues Kill $12B Nestle-Pfizer Deal In Mexico
• Judge Won't Revive FCA Medicaid Case Against Allergan, Novo
• A Closer Look At Dietary Supplement Labels
• FDA Gets No Compounder Oversight Without Doc Release: GOP
• Ex-Celgene, Sanofi, Stryker Execs Accused Of Insider Trading
• FDA Moves Up Device ID Deadline For Implantable Devices
• Sidley Austin Lands HHS Counselor For DC Strategies Group
• U of Calif. Wants SNR Off Caldera's X-Ray Licensing Suit
• Pfizer Says Lipitor Buyers Can't Bring Antitrust Challenge
• Wilson Sonsini Aids Wright Medical In $380M BioMimetic Deal
• Takeaways From HHS Corporate Integrity Agreement Reports
• Diagostic Co. Vermillion Escapes Investor Suit
• DOJ May Bring Charges Against FedEx In Online Pharma Probe
• Investors Opt Out Of Pfizer Securities Fraud Class Action
• Takeda Drops Some Infringement Claims In Dexilant Suit
• Investors Sue Heart-Device Co. Over DOJ Mislabeling Fallout
• Boehner Says He's Not Giving Up On ACA Repeal Plans
• 6 Risperdal Suits To See Appeal Over Marketers' Dismissal
• Long-Delayed $45M Becton Antitrust Deal Wins Court OK
• K-V Pharma Wins 3 More Months To File Ch. 11 Plan
• Actavis Tells Judge Purdue's Oxy Patents Rely On Minor Tweak
• Endo Targets Sandoz, Impex Over Generic Versions Of Opana
• Abbott Cert. Bid Says Nixing Pay-For-Delay Will Kill Innovation
• Insurer Can't Pull Coverage For Sorenson Shoulder Pump Suits
• Botox Maker Offers Up To $375M For Fellow Skin Care Co.
• Novartis Loses Fight With USPTO To Extend 19 Patents
• Relators Face Difficulty Pursuing Safety-Based FCA Suits
• 2 Court Rulings Could Lengthen Term Of Many US Patents
• Reckitt Stages Bid War With $1.4B Schiff Buyout Offer
• Diagnostics Co. Shorted Workers On Stock Options, Suit Claims
• Psychiatrist Took Kickbacks From Teva, FCA Suit Says
• Apotex Can Pursue $60M Fee In BMS, Aventis Dispute: Court
• Mutual Makes Last Plea To High Court For Post-Mensing Case
• Senate Slows Down Controversial Cost-Benefit Analysis Bill
• Sanofi Dodges Amphastar's FCA Suit Over Lovenox
• Pfizer Ducks FCA Suit Over Lipitor Marketing Practices
• Compounders Fault FDA For Deadly Meningitis Outbreak
• FDA Approved Possibly Harmful Generic Acetadote, Suit Says
• Dobbs V. Wyeth: Are We There Yet, And At What Cost?
• GSK Pays $90M To Settle States' Claims Over Avandia Risks
• Advantages Of Inter Partes Review In Hatch-Waxman Cases
• Edwards Wins Invalidity Ruling In Medtronic Patent Row
• Ruling Puts Drug Cos. In Prime Position To Avert State Court
• Zimmer Must Face Most Of Stryker Poaching, Trade Secrets Suit
• House Reps. Want New Health Care Panel To Repeal ACA
• Pernix Inks $101M Deal To Purchase Cypress Pharmaceuticals
• Cumberland Settles 2 Patent Suits Over Generic Acetadote
• Pa. High Court Stifles Appeal In Orthopedics Kickback Suit
• What To Expect From Fungal Meningitis Liability Cases
• FDA Wants Strong Authority Over 'Nontraditional' Compounders
• GE, Cardinal Say Imaging Drug Antitrust Claims Lack Specifics
• German Court Voids AstraZeneca's Seroquel XR Patent
• Medtronic Targeted Over Surgery Imaging Patent
• FDA Marketing Rules Stretch To Drugmakers' Media Pitches
• FDA To Seek More Power Over Compounders At Hearing
• Watson Calls On High Court To Support 'Pay-For-Delay' Deals
• Alnylam Puts Up $65M To End Tekmira Trade Secrets Battle
• SEC Can Use SOX To Claw Back Exec Bonuses, Judge Rules
• Fed. Circ. Affirms $74M Edwards Award In Catheter IP Row
• Divergent Views Of Patent Eligibility Give Little Insight
• Relocation Steps For Wireless Medical Telemetry Users
• Ex-Cephalon GC Joins Cozen O'Connor
• Merck Sues Fresenius To Block Integrilin Generic
• K-V's Makena ITC Suit Would Create Monopoly, Pharmacies Say
• Pfizer Pays $67.5M To End Investors' Pristiq Disclosure Row
• Tips For Quality Control In Technology-Assisted Review
• Ex-Boston Scientific Worker Followed Noncompete, Judge Says
• Coalition Floats Ways To Save Medicare Payments From Cuts
• Q-Med Says $3B Medicis-Valeant Deal Violates Licensing Pact
• Abbott Slaps Watson With Patent Suit Over Niaspan Generic
• Baxter Recalls Buretrol IV Products Over Air Leakage Risk
• FDA Panel Backs Novo Diabetes Drugs, With Conditions
• Arnold & Porter Adds Life Sciences Pro From Biopharma Firm
• AstraZeneca Sues To Block Lupin's Generic Seroquel XR
• The Case For Compounding Pharmacy
• Royal DSM Pays $634M For Nutrient Maker Fortitech
• Buchanan Ingersoll Hires Connolly Bove Pharma IP Atty
• Mylan, J&J Unit Reach Deal In Birth Control Drug Patent Row
• Medical Device Makers Urge FDA To Narrow ID Rule
• Humana Failed To Monitor Drug Refills, HHS Report Says
• Apotex Urges High Court To Nix 'Lead Compound' Patent Test
• Pfizer, Wyeth Lose 3rd Circ. Bid To Toss Pa. Fen-Phen Suit
• Bayer Healthcare Hit With More Mirena Product Defect Suits
• Boston Scientific To Pay Up To $425M For Catheter Maker
• Canada's High Court Kills Viagra Patent In Pfizer-Teva Row
• Missing The Class Action Removal Boat To Federal Court
• Former Chem Rx Execs Dodge Trustee's Suit Over 2007 Buyout
• Judge's Rebuke Of USPTO Paves Way For Longer Patent Terms
• NJ High Court Won't Disturb Novartis Bone Drug Win
• Mass. Official Fired For Ignoring Compounding Center Concerns
• Ex-Guidant Rep. Asks 1st Circ. To Revive Pacemaker FCA Suit
• FTC Resolves Price-Fixing Claims Against Pharmacy Group
• Skelaxin Pay-For-Delay Battle Heads To Pa. State Court
• KV Pharma, Ill. End Medicaid Coverage Dispute Over Makena
• FDA Won't Pull Pfizer Alzheimer's Drug From Market
• Inventions In Unpredictable Fields — Not Always Unobvious
• Qualitest Beats Class Cert. Bid In Birth Control Recall Suit
• FDA Tells DC Circ. It Can't Review Execution Drug Ban
• Dexatrim Maker Beats Suit Alleging Pills Are Unsafe
• Transitions Must Produce FTC Probe Docs, Judge Rules
• Cephalon Urges Fed. Circ. To Revive Fentora Patents
• DOJ Probes Novartis Ties With Specialty Pharmacies
• Takeda Pays $140M To Snap Up Envoy Therapeutics
• Pharmacy Owner Subpoenaed To Testify On Meningitis Outbreak
• Pepper Hamilton Adds Nutter McClennen IP Attorneys
• Novo's Proposed Insulin Drugs Could Pose Risks, FDA Says
• FDA Says Co. Is Trying To Cash In On Meningitis Outbreak
• Citing Sandy, Quigley Seeks More Voting Time For Ch. 11 Plan
• Equistone Buys Sunrise's Wheelchair Division From Vestar
• Obama Win Promises Heightened Push For Product Safety
• What Obama's Re-Election Means For Health Care Policy
• Obama's Tough-Minded FDA Faces Funding Test
• Amgen Tells High Court Investor Class Hinges On Materiality
• FDA Head To Talk Compounder Oversight In Meningitis Hearing
• Myriad Tells Justices To Reject ACLU Gene Patent Challenge
• Novartis Smacked With $10.5M Verdict In Jaw Injury Suit
• A Clarification Of Obviousness-Type Double Patenting
• Ex-Bayer Salesman Wins Award In FCA Retaliation Suit
• Six More Women Join $100M Forest Labs Bias Case
• FDA Approval Can't Nix Allergan Patent Obviousness: Sandoz
• Crisis Management From The Board's Perspective
• Novartis Bone Drug Appeal Won't Get High Court Review
• Hydroxycut Consumers Reach $25M Deal In False Ad MDL
• Atty Must Provide $40M Fen-Phen Deal Info To US: 6th Circ.
• Top 9 Questions About Prop 37
• Pfizer Reports $491M Deal With DOJ Over Rapamune Marketing
• Markey's Post-Outbreak Bill May Fall Short Of Desired Overhaul
• High Court Asked To Reject Appeal Of Post-Mensing Ruling
• J&J Wins Bid To Keep Children's Tylenol Suit In Fed. Court
• Mylan Says Cephalon's Patent Win Could Make Generics Scarce
• Chattem Offers Up To $1.5M To End Mouthwash Suit
• Fed. Circ. Says Woman Didn't Show Vaccine Caused Injury
• UniQure's Glybera 1st Gene Therapy Approved In EU
• How The Presidential Election Could Curtail ADA Regs
• Orthofix Division To Pay $30M To End FCA Kickbacks Suit
• A Twist On Disclosure-Based Shareholder Suits
• Omeros Pays $4M To End Whistleblower's FCA Suit
• DOJ Wants Teva Docs In Connection With FCPA Investigation
• Wal-Mart Beats False Ad Suit Over Joint Health Supplement
• Judge Won't Block Ex-Stryker Exec From Jumping To Zimmer
• Merck Puts Up $39M To Settle Vioxx Class Action
• Gov't Won't Contest Bid To Revive Religious ACA Challenge
• Takeda Escapes FCA Suit Over Undisclosed Drug Complications
• Markey Rolls Out Reform Bill In Wake Of Meningitis Outbreak
• Enzo Wins $49M Verdict In DNA Labeling Patent Row
• J&J Close To Settlement With 845 Plaintiffs In Levaquin MDL
• Top Medical Journal Demands More Trial Data From Drug Cos.
• PhRMA Urges FTC Not To Expand Patent Licensing Scrutiny
• Acura Targets 4 Rivals Over Generic Oxecta Plans
• Fidelity PE Arm Invests $74M In Indian Health Care Co.
• Ex-FDA Head To Testify In GSK Flonase Antitrust Row
• Medtronic Stents Infringe 2 Patents, Suit Alleges
• Johns Hopkins Says Life Technologies Flouts Gene Test IP
• Reversing USPTO Appellate Board Ruling: Not An Easy Task
• Mapping The Pre-Election Landscape